Literature DB >> 1615139

L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction.

K W Lange1, T W Robbins, C D Marsden, M James, A M Owen, G M Paul.   

Abstract

A group of ten patients with idiopathic Parkinson's disease (PD) was tested on a series of automated tests of learning, memory, planning and attention whilst either on or off L-dopa medication. Controlled withdrawal of L-dopa interfered with aspects of performance on three of the tests that had previously been shown to be sensitive to frontal lobe dysfunction; a spatial working memory task, the Tower of London planning test, and a visual discrimination paradigm that also included intra- and extra-dimensional shift tests of selective attention. More specifically, errors were increased in the spatial working memory test, and both the accuracy and latency of thinking were impaired. Thinking time was significantly slowed following L-dopa withdrawal, even though the possible contaminating effects on motor slowing were fully controlled by a yoked control procedure. Nine out of ten patients reached a further stage of the visual discrimination, set-shifting paradigm when on, rather than off, L-dopa medication. Spatial span was also impaired off medication, but there were no effects of L-dopa withdrawal on tests of pattern and spatial recognition memory, simultaneous and delayed matching to sample or visuospatial conditional associative learning. Comparisons with a large control group confirmed previous findings that PD is associated with deficits on the majority of these tests. The results are discussed in terms of the fronto-striatal, dopamine dependent nature of some of the cognitive deficits found in PD, but the apparent dopamine-independent nature of deficits in other aspects of cognitive functioning, notably in tests of visual recognition memory and associative learning.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615139     DOI: 10.1007/bf02245167

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  Planning and spatial working memory following frontal lobe lesions in man.

Authors:  A M Owen; J J Downes; B J Sahakian; C E Polkey; T W Robbins
Journal:  Neuropsychologia       Date:  1990       Impact factor: 3.139

2.  Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction.

Authors:  J J Downes; A C Roberts; B J Sahakian; J L Evenden; R G Morris; T W Robbins
Journal:  Neuropsychologia       Date:  1989       Impact factor: 3.139

3.  Cognitive and motor shifting aptitude disorder in Parkinson's disease.

Authors:  A R Cools; J H van den Bercken; M W Horstink; K P van Spaendonck; H J Berger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

Review 5.  Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates.

Authors:  B Berger; P Gaspar; C Verney
Journal:  Trends Neurosci       Date:  1991-01       Impact factor: 13.837

6.  Deficits on conditional associative-learning tasks after frontal- and temporal-lobe lesions in man.

Authors:  M Petrides
Journal:  Neuropsychologia       Date:  1985       Impact factor: 3.139

7.  Sparing of attentional relative to mnemonic function in a subgroup of patients with dementia of the Alzheimer type.

Authors:  B J Sahakian; J J Downes; S Eagger; J L Evenden; R Levy; M P Philpot; A C Roberts; T W Robbins
Journal:  Neuropsychologia       Date:  1990       Impact factor: 3.139

8.  Cognitive deficits in the early stages of Parkinson's disease.

Authors:  A J Lees; E Smith
Journal:  Brain       Date:  1983-06       Impact factor: 13.501

9.  Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man.

Authors:  A M Owen; A C Roberts; C E Polkey; B J Sahakian; T W Robbins
Journal:  Neuropsychologia       Date:  1991       Impact factor: 3.139

10.  A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease.

Authors:  B J Sahakian; R G Morris; J L Evenden; A Heald; R Levy; M Philpot; T W Robbins
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

View more
  98 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

2.  Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.

Authors:  J S Schneider; J P Tinker; E Decamp
Journal:  Behav Brain Res       Date:  2010-03-27       Impact factor: 3.332

3.  L-dopa impairs learning, but spares generalization, in Parkinson's disease.

Authors:  Daphna Shohamy; Catherine E Myers; Kindiya D Geghman; Jacob Sage; Mark A Gluck
Journal:  Neuropsychologia       Date:  2005-09-16       Impact factor: 3.139

4.  Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease.

Authors:  K Bronnick; U Ehrt; M Emre; P P De Deyn; K Wesnes; S Tekin; D Aarsland
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-26       Impact factor: 10.154

5.  Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.

Authors:  Merle G Paule; Leonard Green; Joel Myerson; Maria Alvarado; Jocelyne Bachevalier; Jay S Schneider; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2012-01-28       Impact factor: 3.763

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

7.  Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study.

Authors:  Antonio Cerasa; Maria Cecilia Gioia; Maria Salsone; Giulia Donzuso; Carmelina Chiriaco; Sabrina Realmuto; Alessandra Nicoletti; Gabriele Bellavia; Aurelia Banco; Marco D'amelio; Mario Zappia; Aldo Quattrone
Journal:  Neurol Sci       Date:  2014-02-20       Impact factor: 3.307

8.  Is there room for new non-dopaminergic treatments in Parkinson's disease?

Authors:  Manuela Pilleri; Konstantinos Koutsikos; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2012-12-11       Impact factor: 3.575

9.  Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.

Authors:  Samuel J Crowley; Guita Banan; Manish Amin; Jared J Tanner; Loren Hizel; Peter Nguyen; Babette Brumback; Katie Rodriguez; Nikolaus McFarland; Dawn Bowers; Mingzhou Ding; Thomas A Mareci; Catherine C Price
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

10.  Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction.

Authors:  T W Robbins; M James; A M Owen; K W Lange; A J Lees; P N Leigh; C D Marsden; N P Quinn; B A Summers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.